NVOWatch

Novo Nordisk

$50.96

Community outlook

Bullish54%

Questions Discussion Earnings Data & analysis

Next report

Wed, 5 Aug 2026

in 7 days

EPS estimate

$5.08

Wall Street consensus

Revenue estimate

$72.2B

Wall Street consensus

Expected swing

±4.1%

±1σ by report day, from realized volatility

Also reporting that week:AMD CAT MCD MRK PFE SPOT DIS LLY

EPS outlook

Odds turned into a number: where the print lands if NVO's usual surprise repeats — and what the crowd's beat odds imply on the same scale.

Street estimate

$•.••

the bar to clear

If history repeats

$•.••

•• of •• quarters beat

Crowd implies

—

needs more forecasts on the beat question

Typical range for the print: $•.•• – $•.••±1σ of past surprises
Beat odds implied by the record: ••%ceiling on •• quarters

A beat probability is a statement about where the print sits relative to the estimate. Scaled by how far recent quarters landed from the Street, it becomes a dollar figure. Not a forecast of the stock — companies fall on beats.

The crowd's read

Live odds from the community — tap through to make your own call.

Will Novo Nordisk be higher in 3 months than today?

Nearest crowd call that settles after the report · 6 forecasting

66%

Forecast

The Street's stance

Analyst consensus — and whether it has been improving or souring into the print.

Hold

37 analysts · 13 buy · 22 hold · 2 sell

steady over the last 3 months

Estimate track record

Reported EPS against the Street's estimate, most recent first — the same feed our earnings questions settle on.

Beat rate

2 of 4

quarters beat the estimate

Avg surprise

+4.1%

vs EPS estimate

Quarter	Estimate	Actual	Surprise	Result
Mar 2026	$5.39	$6.63	+23.1%	BEAT
Dec 2025	$5.96	$6.04	+1.4%	BEAT
Sept 2025	$4.84

Fundamentals snapshot

Trailing-twelve-month figures for context around the print.

Market cap

$1.45T

EPS (TTM)

$27.41

P/E (TTM)

11.9

price ÷ trailing earnings

Revenue growth

+8.1%

TTM vs a year ago

Gross margin

81.8%

of revenue kept after costs

Net margin

37.2%

of revenue kept as profit

52-week range

$224 – $465

now $50.96

Beta

1.83

moves harder than the market

Dividend yield

3.60%

Estimates and reported figures via Finnhub; crowd odds are Novo Nordisk forecasts on Probs. Information, not investment advice.